The latest news of Chengda Bio's listing
According to the data of official website, Chengda Bio is committed to research, development, production and promotion of "international level and domestic leading" biological products. The main products are rabies vaccine for human use and inactivated Japanese encephalitis vaccine for human use. According to public information, Chengda Bio is a holding subsidiary of Liaoning Chengda, a listed company. The actual controller of Liaoning Chengda is the State-owned Assets Supervision and Administration Commission of Liaoning Province.
According to the latest announcement, Chengda Bio plans to issue 4,654,380+0,650 ordinary shares this time. The initial inquiry time is 20265438+0 year 10 month 14. The subscription date of offline issuance and online subscription is 202 1 year 19, and the listing is specific.